Complete resection of recurrent and initially unresectable dermatofibrosarcoma protuberans downsized by Imatinib

World Journal of Surgical Oncology

Volumn 11, Issue , 2013, Pages

  Wicherts, Dennis A ^a   van Coevorden, Frits ^a   Klomp, Houke M ^a   van Huizum, Martine A ^a   Kerst, J Martijn ^a   Haas, Rick L M ^a   van Boven, Hester H ^a   van der Hage, J A ^a  

^a ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

Author keywords

Dermatofibrosarcoma protuberans; Imatinib; Surgery

Indexed keywords

IMATINIB;

ADULT; ARTICLE; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CASE REPORT; CHROMOSOME TRANSLOCATION; DERMATOFIBROSARCOMA PROTUBERANS; DISTANT METASTASIS; HUMAN; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; TREATMENT RESPONSE;

BENZAMIDES; DERMATOFIBROSARCOMA; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; SKIN NEOPLASMS; TREATMENT OUTCOME;

EID: 84874749754     PISSN: None     EISSN: 14777819     Source Type: Journal    
DOI: 10.1186/1477-7819-11-59     Document Type: Article

References (12)

1. Rutkowski P, Wozniak A, Switaj T. Advances in molecular characterization and targeted therapy in dermatofibrosarcoma protuberans. Sarcoma 2011, 2011:959132. 3087969, 21559214.
2. Kransdorf MJ. Malignant soft-tissue tumors in a large referral population: distribution of diagnoses by age, sex, and location. AJR Am J Roentgenol 1995, 164:129-134. 10.2214/ajr.164.1.7998525, 7998525.
3. Criscione VD, Weinstock MA. Descriptive epidemiology of dermatofibrosarcoma protuberans in the United States, 1973 to 2002. J Am Acad Dermatol 2007, 56:968-973. 10.1016/j.jaad.2006.09.006, 17141362.
4. Chang CK, Jacobs IA, Salti GI. Outcomes of surgery for dermatofibrosarcoma protuberans. Eur J Surg Oncol 2004, 30:341-345. 10.1016/j.ejso.2003.12.005, 15028319.
5. Kimmel Z, Ratner D, Kim JYS, Wayne JD, Rademaker AW, Alam M. Peripheral excision margins for dermatofibrosarcoma protuberans: a meta-analysis of spatial data. Ann Surg Oncol 2007, 14:2113-2120. 10.1245/s10434-006-9233-3, 17468914.
6. Rutgers EJ, Kroon BB, Albus-Lutter CE, Gortzak E. Dermatofibrosarcoma protuberans: treatment and prognosis. Eur J Surg Oncol 1992, 18:241-248.
7. Haas RL, Keus RB, Loftus BM, Rutgers EJ, van Coevorden F, Bartelink H. The role of radiotherapy in the local management of dermatofibrosarcoma protuberans. Soft Tissue Tumours Working Group. Eur J Cancer 1997, 33:1055-1060. 10.1016/S0959-8049(97)00026-9, 9376187.
8. Rubin BP, Schuetze SM, Eary JF, Norwood TH, Mirza S, Conrad EU, Bruckner JD. Molecular targeting of platelet-derived growth factor B by imatinib mesylate in a patient with metastatic dermatofibrosarcoma protuberans. J Clin Oncol 2002, 20:3586-3591. 10.1200/JCO.2002.01.027, 12202658.
9. Labropoulos SV, Fletcher JA, Oliveira AM, Papadopoulos S, Razis ED. Sustained complete remission of metastatic dermatofibrosarcoma protuberans with imatinib mesylate. Anticancer Drugs 2005, 16:461-466. 10.1097/00001813-200504000-00014, 15746584.
10. McArthur GA, Demetri GD, van Oosterom A, Heinrich MC, Debiec-Rychter M, Corless CL, Nikolova Z, Dimitrijevic S, Fletcher JA. Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib: imatinib target exploration consortium study B2225. J Clin Oncol 2005, 23:866-873. 10.1200/JCO.2005.07.088, 15681532.
11. Abbott JJ, Erickson-Johnson M, Wang X, Nascimento AG, Oliveira AM. Gains of COL1A1- PDGFB genomic copies occur in fibrosarcomatous transformation of dermatofibrosarcoma protuberans. Mod Pathol 2006, 19:1512-1518.
12. Llombart B, Monteagudo C, Sanmartín O, López-Guerrero JA, Serra-Guillén C, Poveda A, Jorda E, Fernandez-Serra A, Pellín A, Guillén C, Llombart-Bosch A. Dermatofibrosarcoma protuberans: a clinicopathological, immunohistochemical, genetic (COL1A1-PDGFB), and therapeutic study of low-grade versus high-grade (fibrosarcomatous) tumors. J Am Acad Dermatol 2011, 65:564-575. 10.1016/j.jaad.2010.06.020, 21570152.